Navigation Links
Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia
Date:1/22/2009

- Subcutaneous Administration of MSI-1436 in DIO Rats Highlighted -

PLYMOUTH MEETING, Pa., Jan. 22 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today announced a poster presentation of preclinical data on trodusquemine (MSI-1436), Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity, during the Keystone Symposia: Obesity - Novel Aspects of the Regulation of Body Weight in Banff, Alberta.

The poster entitled "Effect of MSI-1436 (Trodusquemine) on Body Weight and Metabolic Profile in Diet-Induced Obese Rats" concluded that a single subcutaneous dose of MSI-1436 leads to marked reductions in body weight, fasting blood glucose, serum triglycerides and cholesterol in diet-induced obese (DIO) rats. In the study, the researchers reported that MSI-1436 induced dose-dependent changes in daily food intake resulting in corresponding decreases in body weight, as well as marked improvements in glucose tolerance and lipid profile.

"The DIO rat is a standard and well-accepted preclinical model for demonstrating anti-obesity impact in this class of drugs. These initial subcutaneous studies of MSI-1436 exhibit dose-related reductions across a wide range of clinical and metabolic outcomes associated with both obesity and diabetes," commented Jack Armstrong, President and CEO of Genaera. "We are continuing to progress the subcutaneous formulation and are planning our initial human studies with MSI-1436 via this route later this year."

About Trodusquemine (MSI-1436)

Trodusquemine is the first highly selective inhibitor of protein tyrosine phosphatase 1B (PTP1B), an enzyme central to controlling the function of both the leptin and insulin pathways. By inhibiting both central and peripheral PTP1B, MSI-1436 is expected to decrease appetite and normalize b
'/>"/>

SOURCE Genaera Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics
2. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
3. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
4. Genaera Corporation Presents Data on Mechanism of Inhibition of PTP-1B for Trodusquemine (MSI-1436) at Federation of American Societies for Experimental Biology (FASEB) Meeting
5. Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
6. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
7. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
8. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
9. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
10. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
11. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... SAN DIEGO , July 29, 2014 /PRNewswire/ ... of Nancy Thornberry to its board ... and franchise head, Diabetes and Endocrinology for Merck ... research, strategy and overall pipeline management in diabetes, ... scientist, initiated and co-led the program that resulted ...
(Date:7/29/2014)... Colo. , July 29, 2014  Encision Inc. ... that prevents dangerous stray electrosurgical burns in minimally invasive ... first quarter ended June 30, 2014. The ... a quarterly net loss of $202 thousand, or $(0.02) ... $2.682 million for a net loss of $311 thousand, ...
(Date:7/28/2014)... -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC ) ... audio webcast to discuss financial results for the second quarter ... 31, 2014 at 4:30 p.m. ET. Conference ... 31, 2014 Time: 4:30 PM ET Listen via Internet: ... A webcast replay will be available on the Pharmacyclics ...
Breaking Medicine Technology:Abide Therapeutics Appoints Nancy Thornberry to Board of Directors 2Abide Therapeutics Appoints Nancy Thornberry to Board of Directors 3Encision Reports First Quarter Fiscal Year 2015 Results 2Encision Reports First Quarter Fiscal Year 2015 Results 3Encision Reports First Quarter Fiscal Year 2015 Results 4Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014 2
... Calif., Sept. 13, 2011 Edison Pharmaceuticals, Inc. announced ... Financing. Capital raised will fund US and European approval ... Terms of the financing were not disclosed. ... Pharmaceuticals is a patient- and physician-founded company devoted to ...
... a leader in Quality of Daily Life Solutions announced ... the agreement, Sodexo will offer technology-enabled solutions by Healthsense ... Sodexo,s current offerings to realize their vision of improved ... communities they serve.   Healthsense is an ...
Cached Medicine Technology:Sodexo Partners with Healthsense to Offer Seniors Technology-Enabled Solutions that Improve Quality of Daily Life 2Sodexo Partners with Healthsense to Offer Seniors Technology-Enabled Solutions that Improve Quality of Daily Life 3
(Date:7/29/2014)... (PRWEB) July 29, 2014 Many people complain ... thing they do each morning is put on glasses to ... These same individuals also may be dissatisfied with their ... , Cataracts may cause difficulty driving, especially at night ... follow or find one’s golf ball, see the TV, sew ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Tylenol ... individuals who allegedly suffered serious liver injuries due ... move forward in a multidistrict litigation underway in ... Liebhard LLP reports. According to an Order dated ... deadlines pertaining to bellwether case and discovery issues. ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 New high ... Medicare Part D by a projected $2.9 to $5.8 ... the actuarial firm Milliman released today by the Pharmaceutical ... D premiums could increase by as much as 8.6 ... C drugs, including Sovaldi and Olysio. , The study ...
(Date:7/29/2014)... Historically, Memorial Day kicks off a three ... throughout that time by picnics, barbecues and beach outings. ... the start of a period that will witness a ... 2012 nearly 1.000 people were killed in crashes involving ... Labor Day. , The summer's warmer weather, longer days ...
(Date:7/29/2014)... Alan Mozes HealthDay Reporter ... certain adult autism patients with just a single dose of ... expressions and emotions, Japanese researchers report. Known as the ... in emotional bonding between lovers, and between mothers and their ... in a key area of the brain that has long ...
Breaking Medicine News(10 mins):Health News:Cataract Surgery: New Technology for Reduced Dependence on Glasses 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Health News:Narconon New Life Retreat Launches New Alcohol Prevention Program 2Health News:'Love Hormone' Oxytocin May Help Some With Autism 2Health News:'Love Hormone' Oxytocin May Help Some With Autism 3
... after having their tonsils and adenoids removed to treat ... over time they may relapse or even worsen. African-American ... from Cincinnati Childrens Hospital Medical Center. , Adenotonsillectomy ... from about 19 per 10,000 in Canada to 115 ...
... 14 Murad, where skincare,meets healthcare(R), today ... the,company,s new Vice President of Global Marketing ... pivotal lead in driving brand growth and ... market,opportunities, driving product development, increasing brand profitability,and ...
... Policy Changes in Handling Credit ... ... today that he has reached a settlement with TransUnion over his,lawsuit against ... TransUnion is the first of six credit reporting companies and banks,which ...
... - Body Mass Index (BMI), the measure of a person,s ... effective prognostic tool for specific types of breast cancer, according ... Cancer Center. , The study, published in the March 15 ... breast cancer (LABC) and inflammatory breast cancer (IBC) with high ...
... PHILADELPHIA Women with breast cancer have more aggressive ... or obese, according to findings published in the March ... the American Association for Cancer Research. , The ... disease, said Massimo Cristofanilli, MD, associate professor of medicine ...
... MNKD ), focused on discovering, developing and,commercializing treatments ... at the Cowen and Company Healthcare Conference on March ... Place Hotel in Boston, MA., Interested parties can ... the,presentation in the Investor Relations section of the Company,s ...
Cached Medicine News:Health News:The ABCs of childhood z's: Snoring may be chronic despite surgery 2Health News:Murad, Inc., Hires Lori Jacobus as Vice President of Global Marketing 2Health News:Leukemia Survivor Reaches Landmark Settlement With TransUnion in ID Theft Case 2Health News:Body Mass Index may serve as prognostic tool for advanced, aggressive breast cancers 2Health News:Body Mass Index may serve as prognostic tool for advanced, aggressive breast cancers 3Health News:Breast cancer more aggressive among obese women 2
Colloidal Gold Conjugated, Protein A - 12 OD...
Polyester ribbons (3) impregnated with different OD values of conjugated Protein G...
Colloidal Gold Conjugated, Protein G - 12 OD...
Colloidal Gold Sol, 40 nm - 50 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Medicine Products: